Nurix Therapeutics, Inc.
NRIX · NASDAQ
11/30/2024 | 11/30/2023 | 11/30/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.88 | 0.08 | -0.09 | 9.70 |
| FCF Yield | -12.25% | -26.56% | -28.57% | -7.28% |
| EV / EBITDA | -6.84 | -2.11 | -3.06 | -10.08 |
| Quality | ||||
| ROIC | -36.69% | -56.16% | -52.29% | -28.48% |
| Gross Margin | -306.30% | -145.69% | -377.64% | -291.37% |
| Cash Conversion Ratio | 0.89 | 0.57 | 0.89 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.19% | 37.29% | 29.42% | -1.48% |
| Free Cash Flow Growth | -102.59% | 47.83% | -91.11% | -1,843.15% |
| Safety | ||||
| Net Debt / EBITDA | 0.40 | 0.16 | 0.29 | 0.58 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -167.72 | 0.00 |
| Cash Conversion Cycle | -8.87 | -8.56 | -1.80 | 55.27 |